HOME//NEWS/Pumis and iCamuno Reach Strategic Cooperation to Develop Two Universal iPSC-CAB-NK Cell Therapy ProductsPumis and iCamuno Reach Strategic Cooperation to Develop Two Universal iPSC-CAB-NK Cell Therapy Products2021-06-14 10:10BACK2022.08.18iCamuno Biotherapeutics: Utilizing Three Platforms to Improve iPSC Differentiation Efficiency2022.01.06iCamuno Biotherapeutics’ Research Results are Selected as One of ‘Science’s Top 10 Scientific Breakthroughs of 2021’BACK
